Obseva (NASDAQ:OBSV) Posts Earnings Results, Beats Estimates By $0.19 EPS

Obseva (NASDAQ:OBSV) issued its quarterly earnings results on Thursday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.19, Fidelity Earnings reports.

Shares of Obseva stock traded up $0.19 on Friday, reaching $3.00. 1,136,800 shares of the stock were exchanged, compared to its average volume of 58,388. The company has a current ratio of 3.67, a quick ratio of 3.67 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $356.09 million, a PE ratio of -1.57 and a beta of 0.82. The business has a fifty day moving average price of $7.74 and a two-hundred day moving average price of $10.14. Obseva has a 1-year low of $2.75 and a 1-year high of $16.49.

A number of research analysts have recently issued reports on OBSV shares. HC Wainwright reiterated a “buy” rating and set a $44.00 price target on shares of Obseva in a research note on Wednesday, September 4th. Credit Suisse Group lowered shares of Obseva from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $16.00 to $4.00 in a research note on Friday. ValuEngine upgraded shares of Obseva from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Obseva from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Obseva in a research note on Sunday, August 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Obseva has a consensus rating of “Hold” and a consensus target price of $24.75.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Further Reading: The four types of profit margin

Earnings History for Obseva (NASDAQ:OBSV)

Leave a Reply

Your email address will not be published. Required fields are marked *